SCHEDULE 13G/A: RA Capital Management Divests Entire Stake in Ensysce Biosciences, Filing Amended Schedule 13G

RA Capital Management, along with its affiliates, has reported a complete divestment of its beneficial ownership in Ensysce Biosciences, Inc., reducing its stake to 0% as of December 31, 2024.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
• The filing indicates that as of December 31, 2024, the Reporting Persons beneficially own 0.00 shares of Ensysce Biosciences, Inc. Common Stock, representing 0.0% of the class.
• This amendment signifies a complete divestment of their previously held stake in Ensysce Biosciences, Inc.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
• The filing includes a Joint Filing Agreement dated February 14, 2025, confirming the collective filing on behalf of all Reporting Persons.

Sentiment

Score: 2

Explanation: The complete divestment by a significant institutional investor like RA Capital Management is a strong negative signal for the company, indicating a lack of confidence or a strategic shift away from the investment.

Negatives

• A significant institutional investor, RA Capital Management, along with its affiliates, has completely divested its stake in Ensysce Biosciences, Inc., reducing its beneficial ownership to 0.0%.

Risks

• The document certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Ensysce Biosciences, Inc.'s future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a specific investment firm's decision to exit its position in a biotechnology company. While not indicative of broader industry trends, it may signal RA Capital's assessment of Ensysce Biosciences within the competitive healthcare and biotech landscape.

Stakeholder Impact

• Shareholders of Ensysce Biosciences, Inc. may view the complete divestment by RA Capital Management as a negative indicator, potentially leading to decreased investor confidence and share price volatility.

Key Dates

Keywords

RA Capital Management, Ensysce Biosciences, Schedule 13G/A, Beneficial Ownership, Divestment, Institutional Investor, Common Stock, SEC Filing, Healthcare Fund